The world scientific community is waging a difficult and prolonged war on cancer. New research in the field of immunogenic cell death can extend the area of drugs application and ensure patients' protection from relapse after therapy.
Under the agreement, Anaeropharma and Chugai conduct joint research regarding specific oncology substances by use of Anaeropharma's i-DPS technology and Chugai's technology
Premier Li Keqiang has recently chaired an executive meeting of the State Council of China, which determined measures of “accelerating the approval of new drugs that have been marketed overseas...